Suppression of the choroidal neovascularization by Thioredoxin

• Project/Area Number: 25861633
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Ophthalmology
• Research Institution: Shimane University
• Principal Investigator: TAKAI YASUYUKI 島根大学, 医学部, 助教 (20397871)
• Project Period (FY): 2013-04-01 – 2015-03-31
• Project Status: Completed (Fiscal Year 2014)
• Budget Amount: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000); Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
• Keywords: HpODE / CNV / TRX / 脈絡膜血管新生 / チオレドキシン / 血管内皮増殖因子 / 酸化ストレス / 脈絡膜新生血管

Outline of Final Research Achievements

The subretinal injection of the lipid hydroperoxide 13(S)-Hydroperoxy-9Z,11E-octadecadienoic acid (HpODE) induced the choroidal neovascularization (CNV) in rat eyes. The incidence of HpODE-induced CNV was reduced in rats treated with thioredoxin (TRX) compared with the control. The concentration of vascular endothelial growth factor (VEGF) was lower in the tissue fluid of rat eyes treated with TRX compared with the control, so TRX may suppress the CNV by reducing the production of VEGF in the rat eyes.